Multiple sclerosis (MS) is an autoimmune-inflammatory neurodegenerative disease that is often accompanied by a debilitating neuropathic pain. Disease-modifying agents slow down the progression of multiple sclerosis and prevent relapses, yet it remains unclear if they yield analgesia. We explored the analgesic potential of fingolimod (FTY720), an agonist and/or functional antagonist at the sphingosine-1-phosphate receptor 1 (S1PR1), because it reduces hyperalgesia in models of peripheral inflammatory and neuropathic pain. We used a myelin oligodendrocyte glycoprotein 35 to 55 ) mouse model of experimental autoimmune encephalomyelitis, modified to avoid frank paralysis, and thus, allow for assessment of withdrawal behaviors to somatosensory stimuli. Daily intraperitoneal fingolimod reduced behavioral signs of central neuropathic pain (mechanical and cold hypersensitivity) in a dose-dependent and reversible manner. Both autoimmune encephalomyelitis and fingolimod changed hyperalgesia before modifying motor function, suggesting that pain-related effects and clinical neurological deficits were modulated independently. Fingolimod also reduced cellular markers of central sensitization of neurons in the dorsal horn of the spinal cord: glutamate-evoked Ca 21 signaling and stimulus-evoked phospho-extracellular signal-related kinase ERK (pERK) expression, as well as upregulation of astrocytes (GFAP) and macrophage/microglia (Iba1) immunoreactivity. The antihyperalgesic effects of fingolimod were prevented or reversed by the S1PR1 antagonist W146 (1 mg/kg daily, i.p.) and could be mimicked by either repeated or single injection of the S1PR1-selective agonist SEW2871. Fingolimod did not change spinal membrane S1PR1 content, arguing against a functional antagonist mechanism. We conclude that fingolimod behaves as an S1PR1 agonist to reduce pain in multiple sclerosis by reversing central sensitization of spinal nociceptive neurons.
Introduction
Multiple sclerosis (MS) is an autoimmune-inflammatory neurodegenerative disease of the central nervous system (CNS) characterized by acute inflammation, demyelination and neuronal loss and associated with severe disruption of the brain, spinal cord, and oculomotor function. 66 Neuropathic pain is one of the most frequent and debilitating symptoms of MS. It is reported by over 50% of the MS population and contributes to an overwhelming decrease in the quality of life. 12, 26, 29, 66 Despite this, neither have determined the underlying mechanisms of or yielded effective treatments for neuropathic pain in MS, 43, 87 although clinical and basic science studies have offered promising leads. 6, 37, 50, 51, 55, 72, 78, 82, 86 Cross-sectional and longitudinal data suggest that MS-associated chronic pain is refractory to older-generation disease modifying therapies. 27 However, whether new-generation disease modifying therapies such as fingolimod are efficacious for neuropathic pain of MS is unknown.
Fingolimod (FTY720; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol) is an FDA-approved immunosuppressive therapy for patients with MS, having shown clinical efficacy for relapsing or relapsing-remitting MS. 17, 48 In vivo, fingolimod is phosphorylated by sphingosine kinase 2 (SPHK2) to its active form fingolimod-phosphate, 8, 31 a potent ligand at 4 of the 5 known S1P receptor subtypes (S1PR1, S1PR3, S1PR4, and S1PR5). 9 Like other S1PR agonists, fingolimod can regulate cellular function through high-affinity receptor binding and then activation of G-protein-coupled receptors, 98 including persistent signaling from internalized S1PR1. 63 In lymphoid organs, fingolimod has an additional mechanism of functional antagonism at S1PR1. This involves irreversible internalization after receptor activation followed by ubiquitination and subsequent degradation; this can occur within minutes and persist for days. 38, 58, 69 S1PR1 is required for chemotactic egress of lymphocytes from lymphoid organs, thus leading to peripheral lymphopenia, 58 so fingolimodphosphate-mediated actions at S1PR1 reduces T-cell numbers in the blood. In MS, reductions in the migration of an autoreactive subset of lymphocyte into the CNS are believed to prevent attacks of the myelin sheath, and thus, reduce the neuromuscular deficits of MS. 9, 16 Repeated administration of fingolimod or fingolimodphosphate reduces behavioral signs of acute and persistent pain in multiple animal models of peripheral inflammation or peripheral nerve injury, including intraplantar formalin 19, 20 or carrageenan, 28 traumatic nerve injury, 20, 97 or the paclitaxel-induced model of chemotherapy-induced neuropathic pain. 44 Its mechanisms of analgesic action, however, are complex and seem to involve both antagonism of pronociceptive S1PR1 signaling in the periphery 28, 44 and direct agonism of antinociceptive S1PR1 signaling in the spinal cord. 19, 97 Despite the fact that fingolimod produces antinociceptive effects in multiple models of peripheral inflammation or injury, 19, 20, 97 its efficacy in central neuropathic pain in an MS model has not been studied. To address this gap, we assessed the effect of fingolimod on neuropathic pain and 3 indices of spinal physiological and cellular activities in an experimental autoimmune encephalomyelitis (EAE) mouse model.
Materials and methods

Animals
A total of 144 female C57BL/6 mice were used in this study: 106 EAE mice and 5 sham at 7 to 9 weeks of age for behavioral and immunohistochemistry studies; and 24 EAE mice and 9 sham at 25 to 28 days of age for calcium imaging studies were purchased from Charles River Laboratories (Indianapolis, IN). Mice were housed 4 in a cage and had access to food and water ad libitum. All procedures were approved by the Institutional Animal Care and Use Committee at the University of Kentucky in accordance with the American Veterinary Medical Association guidelines. Mice were maintained in a temperature (68-72˚F) and humidity (30%-70%) controlled environment on a 14:10 hours light/dark cycle (Lights on: 6:00 AM, Lights off: 8:00 PM). Animals were allowed several days to habituate to the facility before the beginning of the study.
Autoimmune encephalomyelitis induction
Typical MOG models of EAE were designed to generate autoimmune-mediated motor impairment, and this requires adjuvant injection of complete Freund adjuvant (CFA) to enhance neuroinflammatory effects 42, 70 and pertussis toxin to increase circulating peripheral lymphocyte proliferation. 84 However, the severity of these models can compromise behavioral assessment of limb withdrawal and thus preclude the measurement of hyperalgesia. To overcome this confound, Khan et al replaced CFA with Quil A and reduced pertussis toxin concentration, 52 whereas others have reduced MOG concentration so as to induce submaximal EAE. 37, 86 Such milder forms of MOG 33-55 -induced EAE may be more representative of the relapsingremitting form of multiple sclerosis 7, 37 -the form that is FDA approved for treatment with fingolimod. Similarly, we optimized our model with reductions in the doses of MOG , CFA, and pertussis toxin, 32, 71 thus generating an EAE model with a robust pain phenotype and less severe motor paralysis, allowing the assessment of withdrawal behaviors to somatosensory stimuli. injections at D0, animals were given access to DietGel 76A (Clear H2O; Portland, OR), which was replaced approximately every 4 days. As observed previously with this dosing regimen, 71 no animals developed full paralysis of either limb over the 56 days of observation after EAE induction, and thus, all animals could be tested for withdrawal behaviors to somatosensory stimuli.
Behavioral testing
All behavioral measurements including motor scoring and hindlimb withdrawal were performed by a male (TI, experiments 1-3, 7) or female investigator (SD, experiment 8), blinded to group assignments. Mice were acclimated for 30 min/d to individual Plexiglas (4 3 4 3 10-inches) chambers placed on an elevated stainless steel wire mesh for tests of cold and mechanical sensitivities. Mice were acclimated for 2 days before baseline behavioral measurement and for 30 minutes on each testing day. Mechanical sensitivity was evaluated first, followed by cold sensitivity, and then neurological motor function. Baseline testing was conducted before and after EAE induction and at various time points after drug injection (as indicated in the figures).
Neurological motor function
Mice were monitored daily for signs of neurological motor deficits according to the following scale: grade 0, absence of clinical deficits; grade 1, hanging tail or impaired righting; grade 2, mild paresis of 1 hindlimb; grade 3, paresis (weakness) of 2 hindlimbs; grade 4, full paralysis of 1 or 2 hindlimbs/moribund; grade 5, death. 47, 71 We never observed scores of 4 or 5 in this study, thus allowing the monitoring of mechanical and cold sensitivities in all animals.
Mechanical threshold
Mice were acclimated for 30 to 60 minutes in the testing environment within a plastic box (4 3 4 3 10-inches; 3 white opaque walls and 1 clear wall) on a raised metal mesh platform. To evaluate mechanical threshold, we used a logarithmically increasing set of 8 von Frey filaments (Stoelting, IL), ranging in gram force from 0.007 to 6.0 g. These were applied perpendicular to the ventral-medial hind paw surface, with sufficient force to cause a slight bending of the filament. A positive response was characterized as a rapid withdrawal of the paw away from the stimulus fiber within 4 seconds. Using the up-down statistical method, 14 the 50% withdrawal threshold was calculated for each mouse and then averaged across the experimental groups.
Cold response
Cold sensitivity was assessed using acetone drops applied to the plantar surface of the hind paw as previously described. 71 Acetone was applied to the center of the plantar surface of the hind paw using a syringe connected to the PE-90 tubing applicator, flared at the tip to a diameter of 3.5 mm. Surface tension maintained the volume of the drop at 10 to 12 mL on top of the applicator. Under visual guidance, the applicator was gently raised to apply the tip of the drop to the skin, with care to avoid direct contact between the skin and applicator. Acetone is extremely volatile and quickly evaporates, lowering the skin temperature to approximately 6˚C. The duration of time the animal lifted, shook, or licked its paw was recorded. Animals were observed for 60 seconds after each application of acetone. Three trials, with an interval of at least 1 minute between each, were averaged.
Immunohistochemistry
To determine the effect of vehicle or drug on pERK, a lighttouch stimulation protocol was initiated 30 minutes later. As previously described, 36, 39 mice were anesthetized with isoflurane (1.5%). The plantar surface of the left hind paw was gently stroked in the longitudinal plane with a cotton tip for 2 seconds of every 5 seconds, for 5 minutes. After an additional 5 minutes under anesthesia, mice were transcardially perfused with 10% buffered formalin (Fisher Scientific) and the lumbar spinal cord was dissected. The spinal cord was removed and postfixed for 4 hours in 10% buffered formalin followed by 30% sucrose in 0.1 M phospahte-buffered saline (PBS) (Fisher Scientific) overnight. Transverse sections (40 mm) were cut on a freezing microtome and collected in 0.1 M PBS. The sections were washed 3 times in 0.1 M PBS and then pretreated with 3% normal goat serum (Gemini Bio-Products, West Sacramento, CA) and 0.3% Triton X-100 (Sigma Aldrich, St Louis, MO) to block nonspecific binding. Sections were then incubated with a primary antibody for pERK (1:500, #4370, Cell Signaling Technology, Danvers, MA), glial fibrillary acidic protein (GFAP; 1:1000, ab7779, Abcam, Cambridge, MA), or ionized calcium-binding adapter molecule 1 (Iba1; 1:5000, 0,191,971, WAKO Chemical, CA) overnight at room temperature on a laboratory shaker. The tissue was then washed 3 times in 0.1 M PBS and incubated in Alexa Fluor 568 goat anti-rabbit secondary (1:500; Molecular Probes, Grand Island, NY). The tissue was then washed in 0.1 M PBS and mounted with Prolong Gold/49, 6-diamidino-2-phenylindole (DAPI) mounting medium (Molecular Probes, Eugene, OR).
All images were captured with a Nikon TE-2000 microscope and Nikon Elements software. For quantification of pERK, the regions of interest were selected to include lamina I-II of the left (ipsilateral to light-touch stimulation) and right (contralateral to light-touch stimulation) sides at segments L3-L4. An observer who did not know the identity of the slides/sections (eg, blinded to treatment) manually counted punctate immunoreactive profiles in lamina I-II. For GFAP and Iba1, we quantified the mean pixel intensity in lamina I-V of the left and right sides of the dorsal horn at segments L3-L4. Six animals per group and 4 to 6 slices per animal were analyzed for pERK, GFAP, and Iba1. 3 26, and glucose 15, followed by a 20-minute deesterification period in aCSF. Slices were kept at RT in a chamber containing aCSF before recording. For recording, slices were perfused at 1 to 2 mL/min with aCSF in an RC-25 recording chamber (Warner Instruments, Hamden, CT) mounted on a Nikon FN-1 upright microscope fitted with a 79,000 ET FURA2 Hybrid filter set (Nikon Instruments, Melville, NY) and a Photometrics CoolSNAP HQ 2 camera (Tucson, AZ). Relative intracellular Ca 21 levels were determined by measuring the change in the ratio of fluorescence emission at 510 nm in response to excitation at 340 and 380 nm (200 ms exposure). Paired images were collected at 1 to 1.5 seconds/frame. Relative changes in Ca 21 levels were evaluated using Nikon Elements software by creating a region of interest over the cell body and calculating the peak change in the ratio in response to a 10-second exposure to glutamate. Only cells that displayed a consistent response to 1 mM glutamate at the beginning and end of the experiment (showing less than 40% decrease in glutamate-evoked Ca 21 transients) were included. Our previous studies characterized glutamate-responsive profiles as neuronal rather than glial responses, 23 indicating that [Ca 21 ] i responses in the current study predominantly reflect neuronal responses.
Drug preparation and administration
Fingolimod hydrochloride salt was purchased from LC Labs (MA, USA) and 5 mg was dissolved in absolute ethanol (55 mL) and 0.85% sodium chloride (55 mL, Ricca Chemical Company, Arlington, TX) in a 1:999 ratio for experiments 2 to 7. For experiment 8, fingolimod was dissolved in the same vehicle as SEW2871 (Cayman Chemical, Ann Arbor, MI). SEW2871, a selective S1PR1 agonist that produces central effects with systemic administration, 3,95 (3.3 mg) was dissolved in absolute ethanol (165 mL) and Alkamuls EL-620 (165 mL) and sonicated for 5 minutes at 35˚C. Normal saline (1320 mL) was added for a final ratio of 1:1:8 ethanol:Alkamuls:saline. W146, a selective S1PR1 antagonist, 22, 30 was purchased from Cayman Chem (MI). W146 was dissolved in 1 M Na 2 CO 3 (Sigma Aldrich, St Louis, MO), b-cyclodextrin (Sigma Aldrich), and 0.85% sodium chloride (Ricca Chemical Company) in a 1:1:8 ratio, respectively. Repeated administration of fingolimod or SEW2871 was initiated after the onset of neurological motor deficits and painlike behaviors. Daily dosing was chosen for fingolimod because this protocol is sufficient to achieve therapeutic effects in humans 21 and mice; fingolimod has a half-life of 6 to 9 days in humans 21 and 19 to 23 hours in rat after systemic administration. 45, 59 Fingolimod doses of 0.001, 0.01, 0.03, 0.1, or 1 mg/kg (i.p., 200 mL) were chosen based on their ability to exert antihyperalgesic effects in other models of acute and persistent pain in the absence of side effects. 20, 44, 58, 93 In experiment 7A-B, W146 was administered (i.p., 100 mL) 15 minutes before each injection of fingolimod at a dose of 1 mg/kg, which does not produce overt side effects or capillary leakage in the lungs of C57 mice. 74, 80, 99 Vehicle controls did not differ for mechanical hyperalgesia (F 1,4 5 0.043, P 5 0.95) or thermal hyperalgesia (F 1,4 5 3.66, P 5 0.13) and were combined as a single group for comparison of drug treatments (see Figure, supplemental digital content 1, available online at http://links.lww.com/PAIN/A502). In experiment 7C-D, fingolimod and W146 were coadministered. In experiment 8, FTY720, SEW2871, or vehicle were injected daily (i.p.) from D16 to D43. On D44, drug administration was discontinued. Once behavioral scores returned to pretreatment levels, mice were challenged with a single i.p. injection of vehicle, FTY720, or SEW2871 followed by the repeated assessment of mechanical and cold sensitivities. For experiment 9, FTY720 or vehicle was injected daily (i.p.) from D15 to D29 and then spinal cords were harvested using pressure ejection. Lumbar dorsal horn pieces (4 mm) were stored at 280˚C for subcellular fractionation and Western blotting.
Subcellular fractionation
All experiments compared fractions from 2 to 3 independent samples, each obtained by pooling lumbar dorsal horn tissue from 3 mice. Samples were homogenized in 1 mL of sucrose homogenization buffer (10 mM Tris, 30 mM sucrose, pH 7.5), with phosphatase and protease inhibitors (Sigma #P0044, #P5726, #P8340) on ice, and an aliquot was saved for total homogenate analysis. The samples were then centrifuged 31000g for 10 minutes to remove nuclei and debris. The resulting supernatant (S1) was centrifuged (310,000g, 15 minutes, 4˚C) to yield a crude membrane pellet (P2) and the cytosolic supernatant from the P2 fraction (S2). The membrane fraction (P2) was resuspended in 70 mL of 1% SDS. All samples were stored at 280˚C until protein concentration was determined using Bio-Rad DC protein assay (Hercules, CA) according to kit instructions.
Western blotting
Equal amounts of protein (10-20 mg for total homogenates, 5-10 mg for membrane and cytosol fractions) were analyzed by sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis and transferred to the nitrocellulose membrane. We used anti-S1PR1 antibody (1:500, #sc-25489, Santa Cruz Biotechnology, Dallas, TX). The specificity of this antibody has previously been defined by comparing immunostaining of the vasculature in paraffin sections of S1PR1 knockout vs WT mouse embryos. 2 Furthermore, we found that S1PR1 immunoreactivity was absent in spinal cord tissue taken from conditional S1PR1 knockout mouse (see Figure, supplemental digital content 2, available online at http:// links.lww.com/PAIN/A502; tissue kindly provided by Laura SimSelley and Matthew Lazenka from Virginia Commonwealth University). Equal protein loading was ensured by probing the membranes with anti-actin antibody (1:5000, #MAB1501, Millipore Billerica, MA). Fluorescent secondary antibodies were used at 1:20,000 (anti-mouse, abcam #186699; anti-rabbit, abcam #175772, Cambride, United Kingdom). Fluorescent images were taken using an Odyssey imaging system V3.0 (LI-COR Biosciences, Lincoln, NE). Densitometry was performed using Nikon Elements software. 
W146 administration and detection by Liquid chromatography-mass spectrometry (LCMS)/MS
W146 was injected (20 mg, retro-orbital i.v.) into uninjured and EAE mice (15 days postinduction). At either 5 or 20 minutes after injection, mice were sacrificed by direct cardiac puncture followed by light transcardial PBS/heparin perfusion (5 mL over 30 seconds) to clear blood from the brain. Cardiac blood was collected into Eppendorf tubes containing EDTA and centrifuged at 31100g for 10 minutes within 2 hours of collection. The whole brain was harvested and flash-frozen with liquid nitrogen within 2 minutes of perfusion. All samples were stored at 280˚C for 4 days until they were shipped to Cayman Chemical Company (Ann Arbor, MI) for measurement of W146 by LC-MS/MS. Brain samples were homogenized in MeOH using Precellys Evolution (Cayman Item # 16,900) then centrifuged at 34000g for 15 minutes at 20˚C. Three hundred microliters of the supernatant was mixed with 300 mL of MeOH and 75 mL of 2000 ng/ mL VPC23019. VPC23019 was used in place of isotopically labeled W146, which is unavailable, as an internal standard because it is structurally similar to W146. Mouse plasma samples underwent protein precipitation with 150 mL of 300 ng/mL VPC23019; 5 mL of each sample was injected on column.
Because an isotopically labeled W146 does not exist, calibration curves were generated using either brain extract or plasma spiked with isotopically labeled internal standard VPC23019 (Cayman Item #13240), a structurally similar analogue to W146 (0.25-1000 ng/mL, r 2 5 0.998,119 for brain; 1-1000 ng/mL, r 2 5 0.999,302 for plasma). A Waters ACQUITY UPLC with BEH C8 1.7 mm, 100 3 2.1 mm column was used at 25˚C for separation. A solvent gradient (0.1% formic acid in water as solvent A and 0.1% formic acid in acetonitrile as solvent B) was used as follows: 0 to 0.5 minutes, 15% B; 6.5 minutes, 50% B, 6.6 minutes, 95% B, and 8.7 to 10.7 minutes, 15% B. After elution, a Waters Xevo TQD tandem mass spectrometer with electrospray source in positive ion mode was used for spectrometric analysis (W146 m/z 343 ⇒ 138, VPC23019 m/z 373 ⇒ 118). Some plasma samples were outside the linear range and their concentrations are extrapolated based on the linear range. All brain samples, except for the blind blanks, had detectable concentrations of W146 within the dynamic range. We did not see a significant difference in brain W146 concentrations between 5 and 20 minutes in either naive or EAE animals (P . 0.05), and therefore combined time points within each group.
Statistical analysis
For behavioral and Ca 21 imaging studies 1-or 2-way analysis of variance (ANOVA) with repeated measures was followed by pairwise comparisons using JMP 12 (SAS, Cary, NC). For LCMS/ MS results, 2-way ANOVA followed by Fisher exact test was performed using JMP 12. For immunohistochemical studies, effects of dose were analyzed using either 2-way ANOVA followed by Bonferroni multiple comparisons (for pERK) or 1-way ANOVA followed by Dunnett multiple comparison tests (for GFAP and Iba1) using GraphPad Prism 6 software (GraphPad Software, San Diego, CA). For Western blot analysis, the relative abundance of protein in vehicle and fingolimod-treated pairs were compared using nonpaired 2-tailed t-tests.
Results
Autoimmune encephalomyelitis leads to a robust painrelated hypersensitivity that peaks before hindlimb paresis
The EAE model in rodents has extended our understanding of the mechanisms underlying the motor deficits and demyelination associated with the MS disease state. 4, 43, 89 Autoimmune encephalomyelitis is emerging as the model of choice to study MS pain and is now routinely characterized by mechanical and cold hypersensitivity that develops before the onset of severe neurological motor deficits. 43, 68, 71, 73, 96 As illustrated in Figure 1A , control injections of adjuvants (CFA and pertussis toxin, Sham, n 5 5) did not produce neurological motor deficits (P . 0.05). By contrast, MOG plus adjuvants (MOG , n 5 7) produced motor deficits (F 1,61 5 144.13, P , 0.0001; Fig. 1A ) that began 7 days after immunization and lasted throughout the duration of the study (19 days) . Frank paralysis never accompanied hindlimb weakness or impaired movement, thus allowing measurement of noxious stimulus-induced withdrawal behaviors.
MS patients often report mechanical and cold hypersensitivity. 90 We show that EAE mice exhibit robust hypersensitivity to mechanical or cold stimuli in agreement with previous studies. Fig. 1B ) and cold hypersensitivity (F 1,33 5 890.45, P , 0.0001; Fig. 1C ). Mechanical and cold hypersensitivity in EAE animals is significantly different from sham controls (CFA plus pertussis toxin alone) beginning 4 days after the first MOG injection (before the development of motor deficits). Compared with baseline measurements, sham treatment modestly decreased mechanical threshold (F 6,36 5 6.02, P 5 0.0002; Fig. 1B ) and increased cold withdrawal duration only at D4 (F 6,38 5 2.99, P 5 0.017; Fig. 1C ). The next results are presented with the caveat that a nonadjuvant control group was not included. 
Fingolimod dose dependently decreased hyperalgesia in a reversible and repeatable manner
Previous studies indicate that fingolimod reverses the signs of EAE disease including motor deficits, 15, 33, 49, 75, 93 and here, for the first time, we tested the hypothesis that fingolimod reverses EAE-induced pain-like behavior as well. Figure 2 illustrates that fingolimod (0.1 and 1 mg/kg, n 5 4-6) reduced mechanical (F 2,11 5 38.01, P , 0.001; Fig. 2A ) and cold hypersensitivity (F 2,11 5 32.90, P , 0.001; Fig. 2B ) in a reversible and repeatable manner. When fingolimod was discontinued on D34, pain scores gradually returned to pretreatment levels, consistent with the long half-life of the drug.
Fingolimod can decrease hyperalgesia either by direct actions at pain modulatory centers or by indirect actions secondary to amelioration of disease. To dissect these possibilities, we carefully monitored the time course of clinical motor deficits and pain scores. As expected, daily administration of fingolimod dose dependently decreased neurological motor deficits (F 6,35 5 11.84, P , 0.0001, n 5 6 to 7; Fig. 3A) , and the highest dose (1 mg/kg) yielded an onset of action at D27. Also, fingolimod dose dependently reversed mechanical (F 6,35 5 145.78, P , 0.001; Fig. 3B ) and cold hyperalgesia (F 6,35 5 74.00, P , 0.001; Fig. 3C) ; the highest dose inhibited mechanical hyperalgesia and cold hyperalgesia within just 21 days and 18 days, respectively. Close inspection of Figures 3D-F reveals that fingolimod did not alter motor deficits from D0 to D21. Not until later time points (eg, day 30, Figs. 3G-I ) did the effect of fingolimod on motor deficits become significant (P . 0.05). This temporal dissociation in the onset of action of fingolimod on motor deficits and pain-like behaviors suggest that fingolimod acts directly at pain modulatory centers to decrease EAE-induced hyperalgesia.
Fingolimod inhibits physiological and cellular indices of autoimmune encephalomyelitis-induced central sensitization in the dorsal horn
Fingolimod targets spinal nociceptive pathways in the paclitaxel, spared nerve injury (SNI), formalin, and carrageenan models of persistent pain. 20, 28, 44, 97 Therefore, we first asked whether our EAE model is associated with the activation of dorsal horn neurons and then asked whether this activation could be reduced with fingolimod. To address these questions, we evaluated the components of central sensitization in the dorsal horn: Ca 21 mobilization, phosphorylation of ERK, and upregulation of GFAP and Iba1. Central sensitization refers to an exaggerated response of CNS nociceptive neurons to normal or subthreshold afferent input and is believed to contribute to enhanced responsiveness to sensory input after tissue injury. 77 However, the question as to whether EAE generates central sensitization remains unanswered.
An increase in intracellular Ca 21 levels is the key trigger for the initiation of activity-dependent central sensitization in dorsal horn neurons. 54 Recordings in brain slices from EAE mice before the emergence of motor deficits indicated that oral fingolimod reversed the increased duration and frequency of glutamate-mediated spontaneous excitatory postsynaptic currents. 75 Therefore, as our first attempt to detect central sensitization, we first evaluated EAEinduced increase in glutamate-evoked Ca 21 responses with livecell Fura-2 ratiometric analysis in adult spinal cord slices. As described previously, 23 glutamate concentration dependently increased [Ca 21 ] i mobilization in lamina II neurons of dorsal horn slices taken from sham mice (Fig. 4A) . Importantly, this glutamateevoked [Ca 21 ] i mobilization was potentiated in animals treated with MOG (F 1,16 5 9.97, P 5 0.0061; n 5 9; Fig. 4A ). This was reversed in dorsal horn slices obtained from EAE mice treated with 1 mg/kg fingolimod for 7 to 10 days (F 1,13 5 6.80, P 5 0.022; n 5 7 to 8; Fig. 4B ). Our results extend to our previous studies that indicate neuropathic and inflammatory injury potentiates glutamate-evoked Ca 21 signaling in the dorsal horn. This potentiation coincided with the temporal onset and resolution of hyperalgesia. 18, 23 Our second approach to evaluate central sensitization was to measure EAE-induced increase in stimulus-evoked pERK in dorsal horn neurons. Dorsal horn pERK expression is widely used as a marker of central sensitization in models of persistent pain.
18,34,36
Figures 5A-D illustrate that light-touch stimulation evoked pERK staining in the lumbar dorsal horn of EAE mice, largely in NeuNpositive profiles. Stimulus-evoked pERK was greater at the left (ipsilateral) side as compared to the right (contralateral) side of stimulation (P , 0.0001 at 0 mg/kg fingolimod; Fig. 5E) . Figures 5E-G illustrate that fingolimod dose dependently reduced the number of pERK positive cells on the ipsilateral side (F 4,42 5 9.90 P , 0.0001; n 5 4 to 6), but not on the contralateral side (P . 0.05). As illustrated in Figures 5H-L, W146 alone had no effect compared with vehicle (P . 0.05), but reversed fingolimod inhibition of stimulusevoked pERK expression in the dorsal horn (F 3,58 5 5.88, P , 0.001).
To determine whether the S1PR1-selective antagonist W146 crosses the blood-brain barrier, we measured plasma and intracerebral W146 after retro-orbital intravenous injection (20 mg) in non-EAE (naive-W146) and EAE mice (EAE-W146; 15 days post induction). As expected, W146 measurements in the plasma or brain from non-EAE mice that did not receive W146 (naive-blank mice) were below the limit of detection. And as expected, we found high plasma concentrations of W146 when measured 5 minutes after injection (2345 6 136 ng/mL). These concentrations significantly declined within 20 minutes (644 6 50 ng/mL; F 1,14 5 102.7, P , 0.0001) in accordance with its half life. 80 There was no difference in the plasma concentration of W146 between naive-W146 and EAE-W146 (P . 0.05). As illustrated in Fig. 5M , we observed measureable concentrations of W146 in the brain from naive-W146 or EAE-W146 mice (Fisher exact test: P , 0.0001), and these concentrations were higher in EAE mice as compared to naive controls. These data indicate that systemically administered W146 can cross the bloodbrain barrier to block S1PR1 receptors in the CNS, particularly when this barrier is compromised as it occurs in EAE.
Neuronal injury leads to the activation of astrocytes (which express GFAP) and macrophage/microglia (which express Iba1) that then contributes to the development of central sensitization. 35, 83 Spinal cord glial cell activation contributes to central sensitization and pathological pain in a number of pain syndromes with different etiologies, including diabetic neuropathy, chemotherapy-induced neuropathy, peripheral nerve inflammation and trauma, and spinal cord inflammation. 60 Therefore, our third approach to evaluate central sensitization was to measure EAE-induced increases in the dorsal horn GFAP and Iba1. In agreement with previous studies, 68 EAE increased GFAP and Iba1 immunoreactivity. Compared with EAE mice treated with vehicle, fingolimod (n 5 4-6) dose dependently reduced both dorsal horn GFAP (F 4,15 5 5.95, P , 0.01; Fig. 6A-C) and Iba1 (F 4,17 5 3.62, P , 0.05; Fig. 6D-F) .
S1PR1 receptor antagonist W146 prevents fingolimodinduced antihyperalgesia and pERK activation
To test the hypothesis that S1PR1 mediates the development of fingolimod-induced antihyperalgesia, we administered the selective antagonist, W146, 15 minutes before every injection of fingolimod. As illustrated in Figure 7 and similar to Figures 2  and 3 , fingolimod decreased mechanical (F 3,21 5 238.71, P , 0.0001; Fig. 7A ) and cold hypersensitivity (F 3,21 5 22.52, P , 0.0001; Fig. 7B) . When administered at a dose of 1 mg/kg, i.p., W146 prevented fingolimod inhibition of mechanical (F 1,11 5 548.90, P , 0.001) and cold hypersensitivity (F 1,11 5 48.97, P , 0.0001 compared with fingolimod alone, n 5 6-7). W146 alone had no effect compared with vehicle (P . 0.05). W146 alone had no effect on either hyperalgesia or pERK (P . 0.05), arguing against a contribution of ongoing activity of S1PR1 to EAE hyperalgesia and spinal pERK expression.
W146 reverses fingolimod-induced antihyperalgesia
S1PRs can regulate cellular function through the activation of G-protein-coupled receptors 98 or by ligand-induced functional antagonism (receptor internalization and degradation 38, 58, 69 ). To determine whether fingolimod behaves as an S1PR1 agonist rather than as a functional antagonist to inhibit EAE pain, we initiated the administration of W146 after the development of fingolimod-induced antihyperalgesia. We reasoned that if the fingolimod mechanism of analgesia is functional antagonism (irreversible internalization and degradation), then S1PR1s would not be available for antagonist actions of W146. On the other hand, if the fingolimod mechanism of analgesia is S1PR1 agonism as suggested by Scholich et al., 97 then S1PR1s should be available for binding and inhibition by W146. To test this, fingolimod was administered daily (0.03 mg/kg i.p.) from D14 to D34 to produce antihyperalgesia and was then coadministered with W146 (1 mg/kg i.p.) from days 35 to 44. Figures 7C and D show that W146 reversed fingolimod-induced inhibition of both mechanical (F 6,26 5 16.33, P , 0.0001, n 5 4 Fig. 7C ) and cold hypersensitivity (F 6,25 5 3.94, P 5 0.0099, n 5 4; Fig. 7D ), supporting an antinociceptive mechanism of action of fingolimod.
Fingolimod and S1PR1 receptor agonist SEW2871 mediate antihypersensitivity
To further test the hypothesis that repeated injection of fingolimod behaves as an agonist rather than as a functional antagonist, we predicted that its antinociceptive effects would be mimicked with either (1) a selective S1PR1 agonist that does not induce irreversible internalization and degradation such as SEW2871 46, 79 or (2) a single injection. Figure 8A demonstrates that repeated administration of fingolimod decreased neurological motor deficits (F 1,9 5 5.19, P 5 0.049). Importantly, both fingolimod and SEW2871 reduced mechanical ( Fig. 8B ; F 2,13 5 10.05, P 5 0.0023) and cold hypersensitivity (Fig. 8C, F 2,13 5 7.28, P 5 0.0075), n 5 5 to 7.
We then discontinued drug administration, allowed behavior thresholds to return to pretreatment indices of hypersensitivity, and administered a single injection of fingolimod or SEW2871, and then evaluated just von Frey sensitivity and responses to plantar application of acetone. Both drugs reduced mechanical hypersensitivity at 30 minutes after injection ( Fig. 8D; F 2 ,26 5 5.76, P 5 0.009) and cold hypersensitivity at all time points tested (Fig. 8E, F 2 ,23 5 10.68, P 5 0.0005, n 5 8-10).
Fingolimod does not decrease membrane S1PR1
Functional antagonism is associated with internalization and degradation of G-protein-coupled receptors such as S1PR1, 10, 11, 38, 58, 69 leading to large decreases in both membrane and cytosolic compartments. By contrast, agonism leads to receptor internalization and recycling back to the cell surface. This should be associated with minimal changes, if any, in membrane and cytosolic compartments. To further explore whether fingolimod behaves as an agonist or as a functional antagonist in mouse spinal cord, we measured S1PR1 content in both membrane and cytosolic fractions. On day 15 after EAE induction, we confirmed behavioral hyperalgesia, administered fingolimod (0.1 mg/kg) or vehicle daily for 14 days, and then collected and pooled membrane fractions, cytosolic fractions, and total homogenate for Western blot analysis. As illustrated in Figures 9C-F , fingolimod did not change S1PR1 levels in either the membrane or cytosolic fractions of either naive or EAE mice (P . 0.05). Fingolimod did not alter S1PR1 content in the total homogenate of naive mice (Fig. 9G) , but did decrease S1PR1 in EAE mice (Fig. 9H , 80.7 6 3.6% compared with control, P 5 0.033). This latter effect was small (less than 20%) and so perhaps not physiologically significant.
Discussion
Autoimmune encephalomyelitis mice exhibit reliable behavioral measures of neuropathic pain
Consistent with previous studies, 50, 52, 68, 71, 73, 96 we found that mechanical and cold hypersensitivity developed and peaked earlier than motor deficits. The early emergence of pain-like behavior in EAE mice suggests that pain pathways are sensitized independently of the clinical course of the disease well before motor pathology and deficits. Taken together with the lack of hindlimb paralysis, we conclude that neuropathic pain behavior is not confounded by motor impairment in our optimized EAE mouse model.
Spinal nociceptive neurons are sensitized in EAE mice
Clinical studies suggest that MS is associated with the dysfunction of dorsal horn pain modulatory centers that contribute to neuropathic pain. 43 We observed for the first time that EAE potentiated 3 markers of central sensitization in the dorsal horn: (1) glutamate-evoked Ca 21 signaling in dorsal horn slices; (2) light-touch stimulation evoked pERK expression, consistent with previous studies showing that EAE increases the dorsal horn expression of Fos, another marker of cellular activity 67 ; and (3) GFAP and Iba1 immunoreactivity, consistent with previous studies indicating that both astrocyte and macrophage/microglial activation coincide with the onset of mechanical hypersensitivity. 56, 68 Our glutamate bath application likely overrides plasticity at presynaptic glutamatergic terminals, leading us to speculate that the enhanced Ca 21 signaling observed in EAE mice indicates plasticity at postsynaptic sites. This is consistent with enhanced glutamate-mediated excitatory postsynaptic currents, increased expression of GluA1 and phosphorylated GluA1 in the postsynaptic fraction, and increased postsynaptic a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) signaling in corticostriatal slices of EAE mice. 13, 75 EAE also induces presynaptic changes that could contribute to central sensitization. Indeed, neuropathological data indicate that EAE animals exhibit overactive presynaptic N-methyl-D-aspartate (NMDA) receptors, decreased excitatory amino acid transporter-2, and increased glutamate type 1 transporter. 67, 72 4.3. Fingolimod inhibits EAE-associated hyperalgesia through S1PR1 agonism Our data are the first to demonstrate that S1PR1 ligands reverse hyperalgesia (mechanical and cold hypersensitivity) and spinal nociceptive transmission (pERK expression and Ca 21 mobilization in spinal neurons) in EAE. Off-target effects are unlikely because the antihyperalgesic effects of fingolimod were mimicked by SEW2871, and both behavioral and biochemical effects of fingolimod were blocked by W146. Fingolimod mechanisms of analgesic action are complex and seem to involve both antagonism of pronociceptive S1PR1 28, 44 to create a pharmacological "S1PR1-null state" as it does in lymphocytes, 58 as well as direct agonism of antinociceptive S1PR1 signaling. 19, 97 Accordingly, when fingolimod is acting as a functional antagonist, we see similar effects with a competitive antagonist. 91 However, our pharmacological data suggest that fingolimod evokes S1PR1 agonism in spinal nociceptive processing and pain in EAE that is antinociceptive rather than pronociceptive. First, the S1PR1-selective antagonist W146 had no effect alone, but blocked fingolimod-induced decreases in pERK expression. Our studies confirm that the blood-brain barrier is perturbed in our EAE model at 15 days after induction, thus providing a means for W146 to act centrally. Second, W146 had no effect on nociceptive behavior, but blocked fingolimod-induced decreases in both mechanical and cold hypersensitivity. Third, administration of SEW2871, an S1PR1-selective agonist that does not irreversibly internalize S1PR1, mimicked the antihyperalgesic effect of fingolimod is both chronic and single-injection paradigms. Fourth, fingolomod did not change the membrane content of S1PR1, consistent with an agonist mechanism. Our data are consistent with previous reports indicating that intrathecal fingolimod-phosphate inhibited hyperalgesia in the SNI model through S1PR activation rather than irreversible receptor internalization associated with functional antagonism. 97 Our data are consistent with the idea that fingolimod acts as a functional antagonist at lymphocytes to reduce the clinical symptoms of EAE/MS and as an S1PR1 agonist in the CNS to reduce the hyperalgesia of EAE/MS.
Antinociceptive and pronociceptive actions of S1PR agonists
We report that fingolimod and SEW2871 produce antihyperalgesic effects in the EAE model of MS. Pain is a problem in multiple types of MS, 29 and these results may translate not only to the primary progressive form, but also to the relapsing-remitting form of MS that is targeted by fingolimod. 29 Our results are consistent with previous studies demonstrating antihyperalgesic effects of fingolimod in multiple models of acute nociception, peripheral inflammation, and peripheral nerve injury. 19, 20, 28, 97 For example, systemic administration of fingolimod produced antihyperalgesic effects in the SNI model, which was abolished by intrathecal pretreatment with W146. 97 Similar results were observed after intrathecal administration of fingolimod phosphate: inhibition of nociception and mechanical hypersensitivity after intraplantar formalin 20 or SNI, 97 respectively. S1PR1 signaling in the brain may also be antinociceptive because intracerebroventricular administration of SEW2871 reduced noxious heat sensitivity, and this was attenuated by the S1PR1/3 competitive antagonist VPC44116. 85 Conversely, however, S1PR1 agonists can exert pronociceptive actions when administered at peripheral sites or by intrathecal injection. 24, 25, 28, 44, 57, 76 For example, Salvemini and colleagues reported that intrathecal injection of S1P and SEW2871 (0.8 nmol, at 2 hours after injection) produced heat hypersensitivity that could be blocked by local administration of W146 but not its inactive isomer W140 28, 44 and that intrathecal SEW2871 produced mechanical hypersensitivity in uninjured rats. 44 Furthermore, intrathecal W146 (documented as an S1PR1 antagonist) or systemic fingolimod (presumptively acting as a functional S1PR1 antagonist) attenuated hyperalgesia in the paclitaxel model of chemotherapy-induced painful peripheral neuropathy. 44 We suggest that the direction of effect of fingolimod and other S1PR1 agents depends on the pain model and perhaps the site of action. Further studies using sitespecific drug administration are required to determine whether the antinociceptive effects of fingolimod on pain in MS are mediated through supraspinal receptors and/or directly on spinal sites. Regardless, the present results comprise the first demonstration of an effect of S1PR1 agent in a model of central neuropathic pain.
Argument against the mechanism of lymphocyte egress
Kuner et al. recently reported that oligodendrocyte ablation produced a hyperalgesia that coincided with early axonal pathology in the spinothalamic tract and suggested that Figure 8 . Antihyperalgesic effects of repeated and single dosing of fingolimod are mimicked by the S1PR1-selective agonist, SEW2871. (A) Motor function, (B) mechanical, and (C) cold hyperalgesia were monitored before and through 56 days after autoimmune encephalomyelitis (EAE) induction. Fingolimod (FTY720), SEW2871, or vehicle were injected daily (i.p.) from D16 to D43 (yellow; n 5 5-6). On D44, drug administration was discontinued. Once behavioral scores returned to pretreatment levels, mice were given a single injection as indicated and (D) mechanical and (E) cold hyperalgesia were monitored acutely (n 5 8-10). Arrows indicate days of MOG injections. Data represent mean 6 SEM. *P , 0.05 fingolimod compared with MOG 35-55 -treated animals that received vehicle. †P , 0.05 SEW2871 compared with vehicle. oligodendrocyte function is required for normosensitivity to somatosensory stimuli. 40 In the same study, fingolimod administration at doses that inhibited lymphocyte infiltration did not affect the development or maintenance of nociceptive hypersensitivity. Consistent with this idea, in the current study, fingolimod reduced pain behavior more quickly than it ameliorated motor deficits. Second, intrathecal fingolimod produced antinociceptive effects in both formalin and SNI models without alterations in blood lymphocyte count. 20 Third, fingolimod decreased astrocyte and microglial activation in a non-T-cell model of demyelination, the cuprizone model, that does not involve lymphocyte trafficking. 53 We conclude that fingolimod efficacy in EAE-induced pain is produced by central mechanisms that do not involve inhibition of lymphocyte egress/T-cell migration into the spinal cord.
Fingolimod may reduce pain by targeting astrocytes and/or microglia
In addition to its antihyperalgesic actions, we report that fingolimod normalized EAE-associated elevations of GFAP and Iba1 in the dorsal horn. This suggests that fingolimod inhibits the activation of astrocytes and/or macrophage/microglia. Fingolimod readily crosses the BBB and may therefore have direct effects on neurons, astrocytes, and microglia, which readily express S1PR1s. 16, 31, 59 Supporting evidence indicates that fingolimod targets astrocytes and microglia in EAE and MS. 13 is lost in mice lacking S1PR1 receptors, specifically on astrocytes. 15 Thus, it is plausible that fingolimod imparts inhibitory effects on hyperalgesia through direct actions on spinal astrocytes. Second, S1PR1 receptors in cultured microglia bind fingolimod to downregulate the production of proinflammatory cytokines including tumor necrosis factor-a (known to be associated with AMPAR-mediated glutamate transmission in EAE 13 ), interleukin-1b, and interleukin-6. 65 Our data suggest the intriguing hypothesis that in addition to its disease-modifying actions on T-cell function, fingolimod also exerts neuropathic pain inhibitory actions at spinal glia in MS.
Clinical/translational relevance
There are many similarities between EAE and MS including clinical course, pathological CNS lesions, glial activation, and axonal demyelination. 41, 62 Postmortem tissue from MS patients reveal abnormal levels of glutamate and its receptors, 64, 81, 88 suggesting alterations of glutamate transmission similar to that seen in EAE. Multiple sclerosis lesions in humans are characterized by marked reductions in glutamate metabolizing enzymes, glutamate dehydrogenase and glutamine synthetase and the major glutamate transporter GLT-1. 94 Thus, it is plausible that the pain associated with both EAE and MS results from imbalanced glutamate homeostasis. Accordingly, the inhibitory effects of fingolimod on central sensitization, spinal glial activation, and hyperalgesia in our murine model of EAE may be ideally suited to treat MS patients with neuropathic pain.
